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Abstract
In most clinical trials, patients are randomized with equal probability among treatments to obtain an unbiased estimate
of the treatment effect. Response-adaptive randomization (RAR) has been proposed for ethical reasons, where the
randomization ratio is tilted successively to favor the better performing treatment. However, the substantial disagreement
regarding bias due to time-trends in adaptive randomization is not fully recognized. The type-I error is inflated in the
traditional Bayesian RAR approaches when a time-trend is present. In our approach, patients are assigned in blocks
and the randomization ratio is recomputed for blocks rather than traditional adaptive randomization where it is done
per patient. We further investigate the design with a range of scenarios for both frequentist and Bayesian designs.
We compare our method with equal randomization and with different numbers of blocks including the traditional RAR
design where randomization ratio is altered patient by patient basis. The analysis is stratified if there are two or more
patients in each block. Small blocks should be avoided due to the possibility of not acquiring any information from the
µi. On the other hand, RAR with large blocks has a good balance between efficiency and treating more subjects to the
better-performing treatment, while retaining blocked RAR’s unique unbiasedness.
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Introduction
Response-adaptive randomization
Randomization remains a pivotal methodology for advance-
ment in medical knowledge properly done. It removes any
systematic bias and allows direct inference between the treat-
ment group and outcome. Traditionally, a fixed randomiza-
tion scheme (usually 1:1 or 2:1) is used to due to simplicity in
design and execution of the trial. However, response-adaptive
randomization (RAR) designs utilize accrual information to
adaptively tilt the randomization ratio to the better perform-
ing treatment group. Patients enrolled in these trials are
treated to the best way possible, according to current interim
estimates1. However, in traditional RAR confounding of
treatment with time induces a potentially severe bias2–5. The
purpose of this article is to expand on the characteristics
of blocked RAR, proposed by Karrison et al. as a way to
eliminate this bias5. Although, in this paper we focus on
trials with two parallel intervention groups, our method are
easily extendable to three or more arms.
RAR has been highly advocated due to ethical reasons.
It’s primary is that it improves the benefit/risk for the
patients enrolled in a trial6. For instance, in Zidovudine
Treatment (AZT) trial conducted to test the reduction of
maternal-infant transmission of HIV type 1, patients were
randomized 1:17. The equal randomization scheme placed
239 women in the treatment group (AZT) and 238 patients
in the placebo group. Out of the 238 women in the AZT
group, 60 of the infants were transmitted with the HIV virus
while only 20 infants contracted the HIV virus for the AZT
group7. The outcome of the trial confirmed that the new
treatment works. Given the seriousness of the outcome of
this study, it is reasonable to argue that 50-50 allocation was
unethical. As the outcome of the trial becomes available, the
randomization ratio should have tilted in favor of the AZT
group. RAR design could have reduced the number of infants
that contracted HIV disease from their maternal.
On the other hand, opponents of RAR have argued
that adaptive randomization challenges the whole notion
of equipoise2. Hey and Kimmelman also argued that most
new treatments offer small improvement over standard
treatments, thus they offer limited benefit and require a larger
sample size6. Hey and Kimmelman also suggested that equal
randomization helps reduce the trial size and length, thus it
benefits future patients rather than current patients enrolled
in the trial6. Korn and Friedlin measure the difference in
non-responders under equal and adaptive randomization and
found that adaptive randomization required a larger trial to
achieve the same power and type-I error8. Also, outcomes in
RAR trials must be short to be able to obtain the outcome of
the trial for future randomization5.
1Department of Biostatistics & Medical Informatics, University of
Wisconsin-Madison, Madison, WI, USA
2Department of Statistics, University of Wisconsin-Madison, Madison,
WI, USA
Corresponding author:
Thevaa Chandereng, Department of Biostatistics & Medical Informatics,
University of Wisconsin-Madison, 201 WARF, 610 Walnut Street,
Madison, WI 53726.
Email: chandereng@wisc.edu
Prepared using sagej.cls [Version: 2017/01/17 v1.20]
ar
X
iv
:1
90
4.
07
75
8v
2 
 [s
tat
.A
P]
  1
2 S
ep
 20
19
2 Journal Title XX(X)
Time-trend issues
As stated above, a major criticism of RAR is the time-trend
issue. This is a main factor for why RAR is infrequently
used. The type-I error rate is usually not controlled at the
nominal level under traditional Bayesian or frequentist RAR
designs3. Besides affecting type-I error, studies have shown
that there is a large bias in the estimation of treatment
difference under traditional RAR designs3.
Examples of time trend issues in RAR design include4,5:
• The disease itself can change, sometimes radically
(e.g., AIDS in the early 1990s).
• Our definition of the disease can change due to
new scientific discoveries or diagnostic methods (e.g.,
stage migration due to introduction of new diagnostic
technologies).
• Inclusion criteria can change, either formally (in which
case we can stratify analysis on before vs. after the
change) or informally due to recruiting zeal or other
issues (in which case we cant).
• Participating institutions can change, such as when
they even into multi-center trials at different times
• Patients within centers can change, especially but not
only with chronic diseases, due to the phenomenon of
a queue of desperate patients lining up at the door.
• In addition to these examples, an investigator who
wants to game the system could cross his/her
fingers that his favored treatment arm is ahead, then
progressively enroll better prognosis patients over time
In long duration trials, time-trends are especially likely to
occur. Patients’ characteristics might be completely different
throughout the trial or even at the beginning and end of
the trial (which is also known as “patient drift”)5. However,
standard RAR analyses assume that the sequence of patients
who arrive for entry into the trial represents samples drawn
at random from two homogenous populations, with no drift
in the probabilities of success2,5. This assumption is usually
violated. For example, there were more smokers enrolled in
the latter part of the trial than the beginning of the trial in
the Lung Cancer Elimination(BATTLE)9. Kalish and Begg
(1987) noted that in a sampling of large randomized Eastern
Cooperative Oncology Group trials moderate time-trends in
overall outcomes are common10.
Despite the serious flaw in RAR design, there is not
much literature on this area to address the time-trend issue.
A randomization test for adjusting type-I error inflation
was proposed by Simon and Simon using different RAR
rules for double-arm trials11. Jennison and Turnbull explored
a group-sequential method for RAR with continuous
outcome utilizing multi-stage terminology12. Karrison et
al. introduced a stratified group-sequential method with a
simple example of altering the randomization ratio to address
this issue5. Coad used a very similar stratified analysis to
Karrison et al.13. Rosenberger et al. introduced a covariate-
adjusted RAR procedure where time mechanism can be
added as a covariate in the model, at the expense of additional
assumptions14. Thall et al. investigated type-I error under
a linear time-trend induced in the traditional RAR design
and showed that it’s type-I error is significantly above the
nominal level3. Villar et al. explored the hypothesis testing
procedure adjusting for covariates for correcting type-I error
inflation and the effect on power in RAR design with time-
trend effect added to the model for two-armed and multi-
armed trials15.
Time-trend can not only greatly bias the estimated in
treatment effect but it can also wrongly reject a true null
hypothesis. We propose a block (group-sequential) design
where the randomization ratio is altered in a block level
instead of a patient by patient basis using both frequentist
and Bayesian approaches. The randomization ratio is kept
constant in each block. The block design is similar to the
stratified group design introduced by Karrison et al.5. We
further study the robustness in different block sizes using
both frequentist and Bayesian approach. We also compare
these results with traditional RAR design and with fixed (1:1)
randomization.
Trial Design and Simulation
Block Design for RAR and Why?
We assume binary outcomes, in which events (suc-
cess/failure) are observed within a short period from the
beginning of the treatment. In a block design, patients are
enrolled in a sequential manner. For instance, in a two-arm
design (treatments A and B) patients are enrolled in block
with sample size of nAk and nBk, for k = 1, 2, 3, ...,K,
where nAk and nBk represent the sample sizes in treatment
groups A and B in block k. In this design, the randomization
ratio is constant for patients within each block and the
randomization ratio is altered at the block level. Unlike tradi-
tional RAR which potentially alters the randomization ratio
on an individual basis, this method speeds up the process
of RAR trials since the randomization ratio is modified for a
group of patients in the block. The initial randomization ratio
is set to 1:1. As asserted by Karrison et al., the block design
will eliminate bias due to drift through stratification5. How-
ever, the optimal block size remains unclear. Blocks with
a large number of patients also help reduce the probability
of imbalance in the wrong direction, where more patients
are assigned to the inferior treatment compared to traditional
RAR. Blocks with few patients can reduce the power of the
trial because if patients are not randomized to both treatments
in a block, the block becomes uninformative.
Simulation and Design
We investigated the effect of various numbers of blocks using
simulations for both frequentist and Bayesian approach. The
rules for altering the randomization ratio in both Bayesian
and frequentist designs are described in the subsection below.
The target sample size of N = 200 subjects was considered
with number of blocks (strata), K = 1, 2, 4, 5, 10, 20, 100,
200. WhenK = 1 this follows the traditional equal allocation
design and when K = 200 this follows the traditional RAR
design without stratification. Upon completion of enrollment
and collection of data on the subjects in each block, an
interim analysis is done to revise the allocation rule. The
interim analysis also allows for early stopping and details
of early stopping for both Bayesian and frequentist designs
are included below. 10, 000 independent simulations were
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performed for each design yielding a maximum Monte-Carlo
standard error of 0.25%.
In each simulation, the success rate of treatment A (control
group), pA is set to 0.25. The alternative (the success rate of
treatment B, pB) is set to 0.25 (null case), 0.35 and 0.45.
On top of simulating both Bayesian and frequentist designs
for constant pA and pB specified above, we also simulated
RAR with drift effect. To examine the effects of drift, we
increased both pA and pB linearly from their initial values to
a final value of 0.25 larger. The drift was added on a patient
by patient basis. For instance, the success rate in patient
n for treatment A is pA(n) = 0.25 + 0.25(n/200), when n
patient had been accrued. While both the pA and pB , the
treatment effect remains constant throughout the trial. For
both frequentist and Bayesian designs, the final analysis is
done using stratification for a number of blocks K, where
1 < K < 200. For traditional RAR and ordinary with 1:1
allocation ratio the standard analyses are used. Details of
the analysis are attached in the Bayesian and frequentist
approach sections.
Frequentist Approach
The allocation rule for the frequentist approach is altered
using an optimal allocation ratio for 2-armed trial specified
by Rosenberger et al16. The allocation probability for
treatment A in stratum j is defined as
pij,A =
√
pˆA,j−1√
pˆA,j−1 +
√
pˆB,j−1
,
where pˆA,j−1 is the estimated success rate of treatment
A and pˆB,j−1 is the estimated success rate of treatment
B after block j − 1. Simulation for early stopping is also
included. The alpha spending approach was incorporated
to stop for early success or failure17. For traditional RAR
and fixed allocation, a one-sided chi-square test was used
to analyze the outcome. For the block design, a one-sided
Cochran-Mantel-Haenszel test was utilized to deal with the
stratification. Yates’s correction was not applied for both
chi-square and Cochran-Mantel-Haenszel test due to the
overly conservative nature of the correction18. Treatment B is
proclaimed superior to treatment A at the trial’s termination
if the one-sided p-value < 0.05.
The estimated treatment difference is computed as below
for stratified design. In the two treatment scenario ( A &
B), suppose there are K strata, let pAk and pBk be the
proportions of success and nAk and nBk the numbers of
patients in stratum k. Let
δˆk = ˆpBk − ˆpAk
be the observed difference in proportion between treatment
A and B in stratum k. The estimated treatment difference (δ)
is
δˆ =
K∑
k=1
wk δˆk
where wk =
(n−1Ak+n
−1
Bk)
−1∑K
k=1(n
−1
Ak+n
−1
Bk)
−1 is the weight of stratum
k and
∑K
k=1 wk = 1. For a non-stratified design, the
corresponding estimates is
δˆ = pˆB − pˆA
, where pA and pB are the sample proportion of success in
treatment A and B.
Bayesian Approach
In the Bayesian approach, the Bayesian adaptive random-
ization (BAR(1/2)) method used by Thall and Wathen is
employed19. The probability of randomizing subjects to
treatment A in stratum j, pij,A is defined as
pij,A =
(pA>B,j−1(data))1/2
(pA>B,j−1(data))1/2 + (pB>A,j−1(data))1/2
,
where pA>B,j−1(data) is the posterior probability that
treatment A has a higher success rate than treatment B
and pA>B,j−1(data)) = 1− pB>A,j−1(data)) after the j −
1st block . The beta-binomial conjugate prior is used for
the estimation of the posterior probability. The posterior
probability that the treatment A has a higher event rate than
treatment B is
pA>B,j−1(data) ∼
beta(yA,j−1 + a0, NA,j−1 − yA,j−1 + b0)−
beta(yB,j−1 + a0, NB,j−1 − yB,j−1 + b0) > 0,
where yA,j−1 and yB,j−1 denote the numbers of events
in treatment A and B, NA,j−1 and NB,j−1 denote the
numbers of subjects in treatment A and B after block j
- 1, a0 and b0 denote the prior rate parameter of the
beta distribution. Similar to Thall and Wathen’s approach,
Beta(0.5, 0.5) priors were assumed for both treatments A
and B19. Since there is no closed-form solution for the
difference in beta distributed random variables Monte Carlo
simulations were performed to estimate the posterior of the
treatment difference.
Similar to the frequentist design, simulations for the pos-
sibility of early stopping are included. If PB>A,j−1(data) >
.99 the trial is stopped early for success and if
PB>A,j−1(data) < .01 the trial is stopped early for failure.
For non-stratified design, if the final posterior probability
PB>A(data) > .95 treatment B is declared superior to treat-
ment A. The mean treatment difference is estimated using
Monte Carlo simulation using the mean of PB>A(data).
For block-stratified design, Bayesian logistic regression
was implemented to estimate the posterior probability of
treatment difference. The logistic regression model is defined
as below
p ∼ β0 + βtrtxtrt + β1x1 + ..+ βKxk,
where p probability of success, β0 is the intercept term,
βtrt is the treatment effect, xtrt is the indicator variable
for treatment, βj is the stratum effect of stratum j, and xj
is the indicator variable of stratum j, for j = 1,.., K. The
uninformative prior applied in the model are as defined
β0, βtrt, βj ∼ N(0, σ2j ), σ2j ∼ Inv − χ2(1, 2.5).
The posterior value of βtrt is used to estimate the proportion
difference in treatment. The R package arm with quasi
family and identity link with µ(1− µ) variance was used
to fit Bayesian logistic regression and obtain the posterior
samples of βtrt 20. The treatment effect is estimated using
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Figure 1. Distribution of difference in number of patients
assigned to treatment B compared to treatment A (NB −NA)
for a 200 patient trial with no early stopping using both Bayesian
and frequentist stratified designs with 10 number of blocks. The
sample size difference is collected for 100 different simulation
with pA = 0.25 and pB = 0.35. The black dashed line included
shows pi20.
the mean posterior value of βtrt. Treatment B is declared
superior to treatment A if P (βtrt > 0) > 0.95 since βtrt
computes the estimated difference in proportion between
treatment B and treatment A .
Results
For all cases, the simulation was replicated 10,000 times for
both Bayesian and frequentist designs with and without time
trends. The number of blocks are K = 1, 2, 4, 5, 10, 20,
100, 200. For all the simulations, the power (probability of
correctly concluding that treatment B is superior to treatment
A), bias, probability of sample imbalance of more than
20 patients assigned to treatment A over treatment B, the
mean, 2.5%, and 97.5% percentile of difference between
NB −NA (sample size imbalance favoring treatment B
over treatment A) are reported. The power reflects the
proportion of 10,000 trials that declares treatment B superior
to treatment A. The type-I error (false-positive) is simulated
by setting both pA, pB = 0.25. The bias δˆ − δ. pi20, the
probability of assigning 20 or more subjects to treatment
A over treatment B (P (NA −NB > 20)) is included in the
simulation. Due to the nontrivial possibility of assigning
more patients to the inferior arm by chance, it is vital
to analyze pi20. To highlight the main advantage of RAR
compared to equal randomization, the difference in sample
size between the superior arm and inferior arm is presented.
Since the difference between subjects assigned to treatment
B and treatment A (NB −NA) is skewed and dispersed
as illustrated in Figure 1, the mean, 2.5% and 97.5% of
NB −NA are reported.
Simulation with No Time-Trend
Tables 1 & 2 displays the results of simulations for numbers
of blocks, K = 1, 2, 4, 5, 10, 20, 100, 200 using the
frequentist and Bayesian approaches with no drift applied
and not stopping early for success or failure. The frequentist
approach (Table 1) manages to control the type-I error unlike
the Bayesian design in Table 2. Even though the stratified
RAR design has higher type-I error, the type-I error is still
controlled under the nominal level (Table 1). However, the
false-positive rate is high for 4, 5, 10 and 20 blocks under
the Bayesian design (Table 2). Block design with 2, 4, 5
and 10 number of blocks provides a higher power when
pB = 0.35, 0.45 (Table 1). In the Bayesian design, the fixed
randomization ratio provides the best power. Although the
type-I error is close to the nominal level under K = 2, 4 and 5,
with a slight increase in sample size it could be lowered to the
nominal level. A small increase in sample size might still be
favorable if more subjects are treated with the best possible
cure. Blocked designs with a small number of subjects in a
block should not be considered due to low power as shown
in Tables 1 and 2 with 100 blocks. This poor performance is
due to the reality that the blocks will be noninformative if all
subjects in the block receive the same treatment. Ethically,
this design (2 subjects per block) places more subjects at risk
without contributing to the advancement in science.
pB Block Size/Power Bias pi20 NB −NA
0.25 1 0.03 0.00 0.07 -0.35 (-28, 28)
2 0.05 0.00 0.10 0.22 (-34, 34)
4 0.05 0.00 0.14 0.03 (-40, 40)
5 0.05 0.00 0.15 -0.06 (-40, 40)
10 0.05 0.00 0.16 0.08 (-42, 42)
20 0.06 0.00 0.16 0.03 (-42, 42)
100 0.05 0.00 0.17 -0.25 (-44, 42)
200 0.02 0.00 0.16 0.12 (-42, 44)
0.35 1 0.34 0.00 0.07 0.27 (-28, 28)
2 0.46 0.00 0.04 8.64 (-24, 40)
4 0.46 0.00 0.03 13.26 (-24, 52)
5 0.44 0.00 0.03 13.85 (-24, 52)
10 0.44 0.00 0.04 15.24 (-24, 56)
20 0.43 0.00 0.03 16.04 (-24, 56)
100 0.20 0.00 0.03 16.39 (-24, 56)
200 0.34 0.00 0.03 16.32 (-24, 58)
0.45 1 0.85 0.00 0.07 0.19 (-28, 28)
2 0.91 0.00 0.01 14.64 (-16, 46)
4 0.91 0.00 0.01 23.13 (-12, 60)
5 0.90 0.00 0.01 24.80 (-12, 62)
10 0.89 0.00 0.01 27.24 (-10, 66)
20 0.88 0.00 0.00 27.90 (-10, 66)
100 0.49 0.00 0.00 28.79 (-10, 68)
200 0.84 0.00 0.01 28.85 (-10, 70)
Table 1. RAR using frequentist approach with no early stopping
criteria and no drift. pA is set to 0.25 for all cases.
Bias = δˆ − δ. pi20 denote the probability of assigning more
than 20 patients in the inferior treatment group. NA and NB
denotes the number of patients assigned to treatment A and B.
The mean (2.5%, 97.5%) of NB −NA is reported in the last
column. 10,000 simulations were done for each case.
The estimated treatment effect is unbiased under the
frequentist design regardless of the number of blocks used.
However, it is biased for most stratified RAR designs and
traditional RAR as shown in Table 2. Variability in sample
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size assigned to treatment A and B is smaller in the
frequentist approach (Table 1) than the Bayesian approach
(Table 2). The mean difference in the subject’s assignment of
treatment is also smaller in the frequentist design compared
to the Bayesian design. Thus, the frequentist design is more
conservative in assigning patients to the better-performing
treatment than the Bayesian design. At the largest difference
in proportion pB = 0.45, pA = 0.25, there is a possibility
of imbalance in the wrong direction in both designs. The
probability of imbalance in sample size favoring the inferior
treatment is small under all scenarios as shown by pi20
in Table 1. The difference in sample size (NB −NA) is
relatively small and close to 0 for the frequentist design.
On the other hand, the imbalance is large for the Bayesian
design as illustrated by pi20 in Table 2. The large difference in
sample size (more than half the total) is seen in the Bayesian
design.
Tables ?? & ?? display the results of simulations for K =
1, 2, 4, 5, 10, 20, 100, 200 using frequentist and Bayesian
approaches and with early stopping criteria for success or
failure implemented. Parallel to the earlier results, the bias is
higher in Tables ?? and ??.
pB Block Size/Power Bias pi20 NB −NA
0.25 1 0.05 0.00 0.07 -0.08 (-26, 28)
2 0.06 0.00 0.32 -0.54 (-76, 76)
4 0.08 0.00 0.36 -1.15 (-108, 104)
5 0.08 0.00 0.36 -0.47 (-112, 112)
10 0.13 0.01 0.37 1.39 (-124, 124)
20 0.15 0.01 0.38 0.00 (-130, 130)
100 0.01 0.00 0.39 -0.96 (-130, 132)
200 0.07 0.00 0.39 -0.10 (-134, 132)
0.35 1 0.47 0.00 0.07 -0.03 (-28, 28)
2 0.46 0.01 0.06 39.91 (-38, 100)
4 0.45 0.01 0.07 57.26 (-50, 136)
5 0.47 0.02 0.07 61.33 (-52, 144)
10 0.51 0.02 0.07 67.24 (-56, 156)
20 0.58 0.01 0.07 70.34 (-58, 162)
100 0.08 -0.08 0.07 72.26 (-62, 164)
200 0.45 0.01 0.07 71.94 (-60, 164)
0.45 1 0.91 0.00 0.07 -0.04 (-28, 28)
2 0.89 0.01 0.01 69.83 (2, 110)
4 0.87 0.02 0.01 99.05 (12, 150)
5 0.87 0.03 0.01 104.18 (16, 156)
10 0.85 0.03 0.01 113.65 (24, 172)
20 0.87 0.02 0.01 117.41 (20, 176)
100 0.29 -0.12 0.01 119.57 (26, 176)
200 0.87 0.02 0.01 120.42 (28, 176)
Table 2. RAR using Bayesian approach with no early stopping
criteria and with no drift. pA is set to 0.25 for all cases. E(N)
represents the mean sample size for 10,000 simulation.
Bias = δˆ − δ. pi20 denote the probability of assigning more
than 20 patients in the inferior treatment group. NA and NB
denotes the number of patients assigned to treatment A and B.
The mean (2.5%, 97.5%) of NB −NA is reported in the last
column. 10,000 simulations were done for each case.
Simulation with Time-Trend
Tables 3 & 4 display the results of simulations for K = 1,
2, 4, 5, 10, 20, 100, 200 using the frequentist and Bayesian
approaches with 0.25 drift applied and not stopping early
for success or failure. With time drift, the false positive rate
is still under the nominal level for the frequentist design
with all block sizes as seen in Table 3. However, the type-
I error is inflated for traditional RAR and small blocks in the
Bayesian design. Having 2, 4, 5, 10 and 20 blocks remains
the most powerful design with the most extreme difference
in outcome of pA and pB . In the Bayesian design, block
size with 50 subjects is still comparable to the traditional
fixed randomization ratio design, since the type-I error is
controlled under 0.05 and it has the highest power of 0.91
under the maximum difference between pA and pB . A large
number of blocks remains a poor design as illustrated earlier
in Table 2. The estimated treatment difference remains
similar to the simulation with no time-trend except the bias is
a little higher under the traditional RAR design as presented
in Table 4. The difference in sample size, the imbalance in
the wrong direction and the variability between the arms
(NB −NA) remain comparable to the simulation without
time drift applied.
Tables ?? & ?? displays the results of simulation for K =
1, 2, 4, 5, 10, 20, 100, 200 using the frequentist and Bayesian
approach and with early stopping criteria for success or
failure implemented. The output in Table ?? is similar to that
of Table 3 except the treatment different is slightly biased.
However, it is shown that clinical trials with early stopping
are slightly biased compared to trials without early stopping
criteria imposed. Table ?? emphasizes that K = 10, 20, 100
and 200 have inflated type-I errors of 0.14, 0.17 and 0.11
similar to Table 4. As seen regarding type-I error and power
in Tables 4 and ??, small strata should not be considered.
pB Block Size/Power Bias pi20 NB −NA
0.25 1 0.02 0.00 0.07 -0.08 (-28, 28)
2 0.05 0.00 0.04 0.31 (-32, 32)
4 0.05 0.00 0.02 -0.04 (-38, 36)
5 0.05 0.00 0.02 -0.04 (-38, 38)
10 0.05 0.00 0.01 -0.21 (-38, 38)
20 0.05 0.00 0.01 0.08 (-40, 38)
100 0.05 0.00 0.01 -0.02 (-40, 40)
200 0.03 0.00 0.01 -0.10 (-40, 38)
0.35 1 0.30 0.00 0.07 -0.27 (-28, 28)
2 0.41 0.00 0.04 6.85 (-24, 38)
4 0.42 0.00 0.04 11.08 (-24, 48)
5 0.41 0.00 0.04 11.76 (-26, 48)
10 0.40 0.00 0.04 13.18 (-24, 52)
20 0.39 0.00 0.03 13.59 (-24, 52)
100 0.19 0.00 0.03 13.61 (-24, 52)
200 0.30 0.00 0.04 13.37 (-24, 52)
0.45 1 0.81 0.00 0.07 0.01 (-28, 28)
2 0.89 0.00 0.02 12.58 (-18, 44)
4 0.89 0.00 0.01 19.35 (-14, 54)
5 0.88 0.00 0.01 21.09 (-12, 56)
10 0.88 0.00 0.01 23.49 (-12, 60)
20 0.86 0.00 0.01 23.90 (-12, 62)
100 0.46 0.00 0.01 24.17 (-12, 60)
200 0.81 0.00 0.01 24.26 (-12, 62)
Table 3. RAR using frequentist approach with no early stopping
criteria and with 0.25 drift. pA is set to 0.25 for all cases.
Bias = δˆ − δ. pi20 denote the probability of assigning more
than 20 patients in the inferior treatment group. NA and NB
denotes the number of patients assigned to treatment A and B.
The mean (2.5%, 97.5%) of NB −NA is reported in the last
column. 10,000 simulations were done for each case.
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pB Block Size/Power Bias pi20 NB −NA
0.25 1 0.05 0.00 0.07 0.44 (-28, 28)
2 0.06 0.00 0.31 0.50 (-78, 76)
4 0.08 0.00 0.37 0.41 (-114, 114)
5 0.08 0.00 0.38 -0.44 (-120, 122)
10 0.10 0.00 0.39 -0.21 (-132, 132)
20 0.14 0.01 0.39 -0.53 (-136, 138)
100 0.02 0.00 0.39 0.19 (-140, 140)
200 0.14 0.02 0.39 1.03 (-140, 136)
0.35 1 0.41 0.00 0.07 -0.20 (-28, 28)
2 0.42 0.01 0.07 38.53 (-40, 100)
4 0.42 0.02 0.07 59.62 (-54, 140)
5 0.42 0.02 0.08 63.88 (-60, 148)
10 0.42 0.02 0.08 69.54 (-64, 162)
20 0.49 0.02 0.07 73.00 (-62, 166)
100 0.11 -0.07 0.08 74.59 (-66, 168)
200 0.55 0.04 0.07 75.26 (-62, 168)
0.45 1 0.89 0.00 0.07 -0.10 (-28, 28)
2 0.86 0.01 0.01 67.82 (-2, 108)
4 0.83 0.03 0.01 101.98 (12, 152)
5 0.83 0.03 0.01 108.53 (16, 160)
10 0.81 0.04 0.01 118.47 (22, 174)
20 0.82 0.04 0.01 122.37 (26, 178)
100 0.32 -0.10 0.01 124.20 (30, 180)
200 0.90 0.07 0.01 124.62 (28, 180)
Table 4. RAR using Bayesian approach with no early stopping
criteria and with 0.25 drift. pA is set to 0.25 for all cases. E(N)
represents the mean sample size for 10,000 simulation.
Bias = δˆ − δ. pi20 denote the probability of assigning more
than 20 patients in the inferior treatment group. NA and NB
denotes the number of patients assigned to treatment A and B.
The mean (2.5%, 97.5%) of NB −NA is reported in the last
column. 10,000 simulations were done for each case.
Conclusion
RAR designs have the arguably appealing property of
assigning more patients to better-performing treatment.
However, trialists need to be careful with issues of time-
trend. Time-trends can significantly impact the type-I error
rate which can affect the validity of clinical studies.
As statisticians, we cannot emphasize the importance of
controlling the false-positive rate in a clinical setting. Thall
et al. have shown that methods which able to control type-I
error have failed to detect the true treatment difference3.
Besides controlling the false positive rate, trialist needs
to make sure the method of altering the randomization
ratio is not too extreme, affecting the bias and negating the
use of randomization in clinical studies. Thall et al. have
emphasized the difference in simulation between BAR(1)
and BAR(1/2), with BAR(1) having a large imbalance in
the wrong direction and larger false-positive rate. Zelen’s
play-the-winner rule was implemented to an extracorporeal
membrane oxygenation (ECMO) trial where the first patient
was assigned to both control and treatment group21,22. Due
to the failure in the single control and success in the
treatment group, all subsequent patients were randomized
to the treatment group22. However, it was later discovered
that the first patient assigned to the control group was much
sicker than all the patients randomized to the treatment
groups.
On the other hand, scientists need to be aware of the
risk that RAR poses which includes having assigned more
patients to the inferior treatment. As highlight by Thall et
al., “The practical and ethical point is that AR may behave
pathologically in that it carries a nontrivial risk of creating
a large sample size imbalance in favor of the inferior
treatment”3. Large imbalance in the wrong direction can also
be controlled by methods that do not alter the randomization
ratio rapidly.
Bashir et al. have implemented a two-block design where
patients are randomized 1:1 in a group of 10 and then
based on the outcomes, they randomized the next ten patient
to the superior treatment23. However, at the second block,
they randomized patients to the lower dosage because the
probability of randomizing patient to the lower dosage was
0.9 compared to 0.1 to the higher dosage. This design should
be considered a randomized control trial for the first block
and an observational study for the second block.
It is shown that using a small number of blocks (K = 2, 4
and 5) has a good tradeoff between efficiency and ethically
treating patients to the best known superior treatment. A
large number of blocks should be clearly avoided for reasons
of both ethics and efficiency. Traditional RAR does not
only delay the trial but also affects the clinical conclusion
achieved. We have not considered the multiple treatment
design with more than 2-arms. The design would be much
more complex and it should be examined further.
An R package (blockRAR), for the frequentist
and Bayesian models, is implemented in R and
released as open source software under the MIT
license. The blockRAR package is available at
Comprehensive R Archive Network (CRAN) and at
https://thevaachandereng.github.io/blockRAR/. We used
blockRAR version 1.0.0 for all analyses.
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